Regeneron: Driven by Science

For over 25 years, Regeneron's vision has been to build an innovative company that consistently brings new medicines to patients with serious diseases.

Recent News

Regeneron Presents Positive Interim Data from Phase 2 Proof-of-Concept Study of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

05/31/16

TARRYTOWN, N.Y., May 31, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that positive preliminary results from an ongoing proof-of-concept study of evinacumab (REGN1500) in patients with Homozygous Familial Hypercholestrolemia (HoFH) were presented at the 84th Eu...

Read more

Upcoming Events

Evinacumab Presentation at EAS

05/31/16

View Event

R&D Deep Dives with Large Biotech Companies - REGN Fireside Chat

05/31/16

View Event




Close
Form content here please :)